[Pharmacologic treatment of benign prostatic hyperplasia].
Medical treatment for benign prostatic hyperplasia is reviewed by the author. Experiences with herbal extracts have been known for more than 2 decades. Treating benign prostatic hyperplasia with these extracts are recommended in initial phase. Effectiveness of these drugs are approved by some placebo controlled double blind studies. However effectiveness of these are not as good as medical drugs'. It is well known that they have no side effects and are cheaper than medicines. Prostate volume is decreased and mechanical component of dysuria is improved by treating for long time (months, years) with 5 alfa reductase finasterid which contain hormone. This drug is indicated when volume of the prostate is over 40 g. Dynamical component of benign prostatic hyperplasia is treated with a receptor blockers which act on the bladder neck. These medicines effect earlier and are recommended for all benign prostatic hyperplasia patients independently of prostate volume. These might have some side effect like hypotension.
Semmelweis Egyetem, Altalános Orvostudományi Kar, Urológiai Klinika, Budapest.
Imre
I
Romics
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D017292:Doxazosin / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008517:Phytotherapy / Q000379:methods*; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000175:diagnosis* / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D000077409:Tamsulosin
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D011799:Quinazolines; D013449:Sulfonamides; D018120:Finasteride; C041226:Terazosin; C047638:alfuzosin; D000077409:Tamsulosin; D017292:Doxazosin; D011224:Prazosin